Rigel licenses VEPPANU (vepdegestrant) from Arvinas/Pfizer; $70M upfront plus milestones

RIGEL PHARMACEUTICALS INC

Upfront payment of $70M, plus $15M on transition completion; total potential milestones up to $320M.
Tiered royalties on net sales from mid-teens to mid-twenties percent; sublicense revenue sharing.
Rigel gets exclusive worldwide rights to develop, manufacture, and commercialize VEPPANU.
VEPPANU approved in US for ER+/HER2- ESR1-mutated advanced/metastatic breast cancer.
Deal subject to HSR waiting period expiration or termination.

item 1.01

Source: SEC EDGAR

accession 0001034842-26-000038

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.